INNOCOS, a global platform connecting beauty, wellness and longevity leaders, will hold its Luxury Beauty & Longevity Summit in Paris on April 16–17, bringing together global luxury players, founders of research‑driven brands, longevity clinics and diagnostic platforms.
In this guest column, INNOCOS Founder and CEO Iryna Kremin gives a preview of some the key topics under discussion at the Paris summit and explains how luxury beauty players should approach longevity and why layering diagnostics and clinical depth with heritage, as well as leaning into long‑term programs and memberships, rather than single products, will be key to winning in this space
BW Confidential is pleased to offer a 30% discount on tickets to the Luxury Beauty & Longevity Summit Paris on April 16-17. Take advantage of this special offer here
Key takeaways
- Longevity is shifting beauty from anti‑aging claims to measurable healthspan and biological‑age benefits.
- Science‑led challengers are redefining status with proprietary peptides, mechanisms and proof, not just storytelling.
- European luxury has a unique edge: it can layer diagnostics and clinical depth under rich heritage, ritual and emotion.
- The next competitive battleground is long‑term programs and memberships, not single products.
- Brands that blend desire and data, credible science, plus cultural and sensory richness, will lead the new era of “longevity luxury.
Longevity has quietly become beauty’s most powerful new word. For years, “anti‑aging” meant smoothing lines and improving texture; now, the conversation has shifted to healthspan, biological age and cellular resilience. Consumers don’t just want to look better; they want proof that their skin, and ideally their whole organism, is aging more slowly.
In Europe, and particularly in France, luxury houses have long been associated with aspiration and emotion. But a new wave of science‑led challengers is rewriting the rules of what consumers expect from a cream, a clinic, or a program. Longevity is no longer just a claim; it is becoming a strategy. The question for luxury is not whether to respond, but how.
The new playbook of science‑led challengers
Science‑led challengers have built their entire proposition around mechanisms rather than mythology. Instead of talking about a rare flower or a distant glacier, they talk about senescent cells, skin biological age, NAD+ or mitochondrial function. Their engines are proprietary peptides, epigenetic technologies, and targeted complexes designed to act on specific aging pathways. They back up those stories with clear endpoints: measured changes in skin density, barrier function, wrinkle depth or even biological‑age scores.
What’s striking is their communication style. These brands lead with performance: before/after imaging, third‑party clinicals, simple visualizations of complex biology. They borrow the language of biotech and diagnostics, but translate it into consumer‑friendly narratives that can live on social media as easily as in a dermatologist’s office. For European consumers increasingly immersed in wellness, medical aesthetics and biohacking culture, this feels intuitive rather than intimidating. “Longevity is not about who says ‘longevity’, it’s who can prove it. A longevity brand is based on evidence; it’s based on data,” explains Carolina Reis Oliveira, Co-founder and CEO at OneSkin.
This ecosystem thinking is not limited to beauty. Longevity pioneers like Dr Kevin Slawin are already building families of companies around a single scientific platform, spanning therapeutics, cosmetics, and even beverages, so the same ageing science can touch multiple parts of daily life.
In this landscape, luxury no longer competes only with its traditional peers. It competes with companies that behave like mini‑labs, speak like scientists, and operate with the agility of start‑ups. They are setting a new benchmark for what “serious” skincare and wellness look like.
Where European luxury already has an edge
European luxury is not starting from zero. French and Swiss houses in particular have a long history of drawing on medical and spa traditions: cellular cosmetics in Switzerland, dermocosmetics in France, thalasso and clinic‑linked spas from the Riviera to the Alps. They understand how to build worlds – architecture, texture, scent, ritual, that turn a routine into an experience.
Their natural advantage is emotional capital. A jar of cream on a Parisian vanity or a cabin in a Geneva spa carries decades of storytelling, craftsmanship and cultural resonance. Consumers do not only buy efficacy; they buy how a product makes them feel about themselves and their place in the world. This is territory luxury knows well.
Longevity, if handled intelligently, can deepen this advantage. Diagnostic touchpoints, personalized protocols and proprietary complexes don’t have to sit in a separate clinical universe. They can become the “hidden chapter” of the brand story: the reason the ritual works as well as it feels. Rather than abandoning poetry, European luxury has the opportunity to add a robust scientific backbone beneath it.
The question is: can heavy science elevate desirability, or does it risk commoditizing it? The most interesting answers come from brands that refuse this binary and choose “both.
True results come from carefully designed week‑long programs that activate mechanisms like autophagy, not just a single spa treatment, and real longevity is ‘not about high spas and light therapy’ alone, but about holistic programs that combine monitoring, screening and medical and non‑medical interventions to enhance health and longevity.
Three lessons luxury can take from challengers
The first lesson is to move decisively from ingredients to mechanisms. For decades, the hero of luxury skincare was the rare raw material: a caviar extract, a flower that blooms once a year, a mineral from a distant mountain. The new hero is what that ingredient actually does. Does it reduce senescent cell burden? Support barrier repair? Influence mitochondrial efficiency or autophagy? Consumers may not remember every biological term, but they increasingly understand that “how it works” matters more than “where it comes from.”
“If you want to think biology and regeneration, take a step back and stop thinking only about an active or a formulation; think first about a system,” comments Elsa Jungman, Founder and CEO of HelloBiome.
The second lesson is to make proof part of the story, not a technical annex. Challengers don’t hide their data in the back of a brochure; they lead with it. Luxury can adopt the same discipline, while keeping its own tone of voice. That might mean expressing complex studies as simple, human metrics: “skin looks X years younger biologically,” “hallmarks of aging targeted,” “measurable improvement after Y weeks”, and integrating those into in‑store experiences, spa protocols and digital storytelling.
The aim is not to turn every client into a scientist, but to give them the reassuring sense that emotion and evidence are aligned. “It’s really important to talk about the function of the skin, not just its structure. Longevity at the level of the skin is optimizing function.” says Saranya Wyles, Director, Regenerative Dermatology & Skin Longevity Lab at Mayo Clinic.
The third lesson is to think in programs, not products. One of the clearest signals from the longevity world is the rise of memberships, protocols and journeys. Consumers don’t just want a jar; they want an ongoing relationship that adapts to their data and their life stage.
For European luxury, this is fertile ground. Imagine a Paris‑ or Geneva‑based house offering a long‑term “skin longevity journey” that combines diagnostics, tailored formulations, spa treatments, lifestyle guidance and perhaps nutrition, delivered through a mix of physical and digital touchpoints. It’s not a product line; it’s a subscription to better aging, wrapped in a luxury universe.
“When we see patients, the first thing we do is optimize their skin health, which includes optimizing their systemic health – sleep, movement, nutrition, stress reduction, and then all the injectables, lasers and skincare are layered on top of that systemic health,” Wyles underlines.
The most valuable businesses will be those that own the relationship over time, not just the transaction. Luxury is uniquely positioned to deliver that kind of long‑term, emotionally resonant relationship, provided it embraces the operational discipline and data literacy that longevity demands.
The European opportunity: a new luxury language
Europe, and France in particular, is well placed to define a nuanced “longevity luxury.” The region combines strong dermocosmetic science, respected medical aesthetics, and a deep culture of ritual and pleasure. It also sits at the crossroads of global influences: Asian preventive philosophies, American performance culture and a growing Middle Eastern appetite for wellness travel and high‑end clinics all meet in European capitals and airports.
The opportunity is to develop a language in which biomarkers and biological age are not cold numbers, but new expressions of care and refinement. Where a diagnostic is not a hospital experience, but the first step in a beautifully designed journey. Where a proprietary complex is not just IP, but part of a brand’s mythology, its secret code for protecting time.
What science‑led challengers have done is prove that consumers are ready to engage with longevity on these terms. What European luxury can now do is elevate that engagement: making it more sensual, more culturally grounded and more holistically human. Longevity, in this sense, is not a threat to luxury; it is its next great narrative, and it is exactly this new chapter that we will be unpacking together at INNOCOS Paris on April 16–17.
Iryna Kremin is the Founder & CEO of INNOCOS, a global platform connecting beauty, wellness and longevity leaders through summits, awards and curated communities. A passionate biohacker and student at the Geneva College of Longevity Science, she focuses on evidence‑based approaches to healthier, longer lives. Through INNOCOS events and her Beauty Biohacks podcast, she explores how science, luxury and culture intersect and how brands can turn longevity from a trend into a meaningful, value‑creating strategy.